20 Posts Not To Miss From ISTH 2025

The ISTH 2025 Congress took place in Bangkok, Thailand, from June 21 to 25, bringing together thousands of experts in thrombosis, hemostasis, and vascular biology from around the globe. Hosted by the International Society on Thrombosis and Haemostasis (ISTH), the congress continues to serve as a premier platform for advancing research, clinical practice, and education in blood-related disorders.

This year’s meeting delivered a rich, multidisciplinary program covering cutting-edge developments in thrombosis, bleeding disorders, coagulation, platelet biology, and emerging therapies. From novel anticoagulants and gene therapies for hemophilia to updates in cancer-associated thrombosis and COVID-related coagulopathy, ISTH 2025 highlighted the rapidly evolving science driving the field forward. The agenda featured plenary sessions, late-breaking abstracts, award lectures, and expert-led discussions that bridged basic science with real-world clinical applications.

With a strong international presence and hundreds of abstracts presented, the congress fostered collaboration and dialogue across specialties. Special focus was placed on early-career professionals through dedicated networking opportunities, mentorship sessions, and career development forums, reinforcing ISTH’s ongoing commitment to nurturing future leaders in hematology.

Now a cornerstone event in the hematology calendar, the 2025 edition reaffirmed ISTH’s mission to improve patient outcomes through innovation, evidence-based care, and global cooperation. As scientific discoveries accelerate, ISTH 2025 provided a crucial space to connect, learn, and shape the future of thrombosis and hemostasis care.

Our team at OncoDaily has curated 20 key highlights from ISTH 2025. Scroll down to explore the most impactful sessions, hear from thought leaders, and stay ahead of the latest trends in blood science and patient-centered care.

Ruah Alyamany:

“TTP Guidelines Updates ISTH 2025.”

Maryam Maqsood:

“ISTH 2025”

Marc Carrier:

“Meta-analysis presented at ISTH 2025 and simultaneously published in EHJ Editor-in-Chief found that several risk factors (e.g., previous history of VTE or bleeding, advanced cancer, and specific cancer sites) are associated with recurrent VTE and bleeding in patients with CAT.
https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf453/8170116”

Tara Lech PharmD, CACP:

“Treatment of VTE does NOT end at discharge!We need a clinical framework in place to follow pts and allow for early detection of post VTE symptoms and patient reported concerns that impact Quality of Life ISTH2025”

Mercedes Gasior:

“Presenting our experience in ISTH 2025
“BLEEDING AND THROMBOSIS IN MYELOPROLIFERATIVE NEOPLASMS: A FEMALE PERSPECTIVE”.”

Sakditad “Tew” Saowapa, MD:

“Excited to share our work at International Society on Thrombosis and Haemostasis (ISTH) in Washington, DC! Poster PB0518. Thrombotic Outcomes in Pancreatic Cancer Patients on Pembrolizumab vs. Erlotinib. Our real-world data shows pembrolizumab is associated with lower risks of acute DVT and all-cause mortality.”

Meta Analysis Academy:

“Huge congrats to our Meta Master Dr Bezalel MBBS, who is a dear Meta Academy alumni and a resident in India.Congrats for winning a $2000 World Travel Award to present his meta-analysis at  ISTH 2025 in Washington, DC!His presentation was yesterday, proving that great science knows no borders.”

Marc Carrier:

“In non-critically ill patients with COVID-19, therapeutic-dose anticoagulation reduced organ support, thrombosis, and death by 28 days, but increased bleeding risk (though absolute risk stayed low). No high-credibility effect modifiers found. Great work Tobias Tritschler! ISTH2025″

Sakditad “Tew” Saowapa, MD:

“This might just be the ultimate hematology combo — ISTH meets ASH! Who’s ready to play a round of “Name That Cell” with these ASH Image Bank flashcards?”

Flora Peyvandi:

“Here you could find what are the area of research of Angelo Bianchi Bonomi Hemophilia Thrombosis Centre and what we present during the ISTH2025. Hope to see you soon.”

Sakditad “Tew” Saowapa, MD:

“Grateful to be part of the “How to Improve Your Poster” masterclass at ISTH2025. Big thanks to  Dr. Jordan Shavit and Dr. Angela Weyand from the University of Michigan for their insightful advice and thoughtful feedback . Their comments truly helped shape how I communicate science visually and clearly. Also loved meeting fellow early career researchers from around the world. Excited to keep learning and growing together in this field!”

Marc Carrier:

“SPECTACULAR RCT at ISTH2025! Although non-inferiority to CTPA wasn’t shown, a negative SPECT V/Q scan led to low 3-month VTE risk.  Supporting the safety of ruling out PE with a SPECT-based algorithm. SPECTacular findings indeed!”

Cathy Harrison:

“Absolutely incredible results from large >16k women prospective study improving maternal morbidity & mortality through proactive interventions to prevent PPH ISTH 2025”

Tzu-Fei Wang:

“Both physical and mental QoL are significantly affected by VTE complications, important patient reported outcomes from the Garfield study!
Nicola Potere, MarcCarrier, ISTH 2025”

Flora Peyvandi:

“ISTH acute cerebral ischemia mainly at frontal cerebral lobe in iTTP patients ISTH 2025.”

Mercedes Gasior:

“Importance of coagulation assessment in Phi- Myeloproliferative Neoplasms patients” on ISTH 2025″

Alfonso Rodriguez:

“Grateful to have 2 abstracts accepted for poster presentation at ISTH 2025, as well as receiving an Early Career Award! I’ll continue to present our work using large population-scale biobanks to describe venous and arterial thrombosis in known or unknown thrombophilias.”

Thomas Reiser:

“What an inspiring ISTH2025! It was wonderful to host the global thrombosis & hemostasis community in DC. From latest science & innovations to networking & building new collabs – it had it all! Look out for recordings & other post-ISTH updates. Goodbye & see you  ISTH 2026!”

Tzu-Fei Wang:

“How to manage cancer patients with small #VTE (distal DVT and SSPE)? Poster presentation by Roger Kou at ISTH 2025 showed that AC is associated with a lower risk of recurrent VTE in distal DVT!! Marc Carrier , DellucAurelien, Dr.Le Gal.”

Alfonso Rodriguez, MD:

“Happy to have presented both posters at ISTH2025! No picture from the moderated poster presentation but it was also a success!”

To stay on top of everything happening at ISTH 2025, keep following OncoDaily.

Written by Nare Hovhannisyan, MD